Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non- small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials Article

Shapiro, WR, Mehta, MP, Langer, C et al. (2007). Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non- small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials . JOURNAL OF CLINICAL ONCOLOGY, 25(18_suppl), 2010-2010. 10.1200/jco.2007.25.18_suppl.2010

cited authors

  • Shapiro, WR; Mehta, MP; Langer, C; Bezjak, A; Timmerman, R; Brachman, D; Suh, J; Smith, JA; Phan, S; Renschler, MF

authors

publication date

  • June 20, 2007

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Lung
  • Lung Cancer
  • Neurosciences
  • Orphan Drug
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 2010

end page

  • 2010

volume

  • 25

issue

  • 18_suppl